Target e*CRF Used in Arthritis & Rheumatism Publication in Polyarticular Juvenile Idiopathic Arthritis



As part of Target Health’s commitment to academic research, we are pleased to announce that an article entitled “Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis” has been published in the December 19, 2011 online edition of Arthritis & Rheumatism. The authors were kind enough to “thank Target Health Inc. for providing and partially subsidizing the electronic data capture system and electronic data base.”


This study, started in 2007, was performed to determine if aggressive treatment initiated early in the course of rheumatoid factor positive or negative polyarticular juvenile idiopathic arthritis (poly-JIA) can induce clinical inactive disease (CID) within 6 months. The study was conducted in 85 children aged 2 to 16 years with poly-JIA of less than 12 months duration. In Arm 1, patients received either methotrexate, etanercept, and prednisolone, or methotrexate (same dose as Arm 1), or etanercept placebo, and prednisolone placebo (Arm 2).


Results showed that by 6 months, 17 of 42 (40%) of patients in Arm 1 and 10 of 43 (23%) in Arm 2 had achieved CID (p = 0.088), and after 12 months, 9 patients in Arm 1 and 3 in Arm 2 achieved clinical remission on medication (p = 0.0534).


According to Dr. Carol Wallace and her passionately dedicated team, although this study did not meet its primary endpoint, early aggressive therapy in this cohort of children with recent onset polyarticular JIA resulted in substantial proportions of patients in both arms achieving CID by 6 months and clinical remission on medication within 12 months of treatment.


For more information about Target Health contact Warren Pearlson (212-681-2100 ext. 104). For additional information about software tools for paperless clinical trials, please also feel free to contact Dr. Jules T. Mitchel or Ms. Joyce Hays. The Target Health software tools are designed to partner with both CROs and Sponsors. Please visit the Target Health Website at


Leave a Reply

You must be logged in to post a comment.